Use of expedited partner therapy for pregnant women treated for sexually transmitted infections in Gaborone, Botswana.


Journal

Sexually transmitted diseases
ISSN: 1537-4521
Titre abrégé: Sex Transm Dis
Pays: United States
ID NLM: 7705941

Informations de publication

Date de publication:
24 Jan 2024
Historique:
medline: 2 2 2024
pubmed: 2 2 2024
entrez: 1 2 2024
Statut: aheadofprint

Résumé

Partner notification and treatment for sexually transmitted infections is critical to prevent reinfection and reduce transmission. However, partner treatment rates are low globally. Expedited Partner Therapy (EPT), in which the patient delivers treatment directly to their partner, may result in more partners treated. We assessed partner notification and treatment outcomes among pregnant women in Gaborone, Botswana, including EPT intent, uptake, and effectiveness. The Maduo study was a cluster-controlled trial evaluating the effect of antenatal C. trachomatis (CT) and N. gonorrhoeae (NG) infection screening in pregnant women. The intervention arm received screening at first antenatal care (ANC), third-trimester, and postnatal care (PNC) visits. The standard-of-care arm received screening postnatally. Participants screening positive were given options for partner treatment: contact slips, in-clinic treatment, or EPT. Self-reported partner notification and treatment outcomes were assessed at test-of-cure visit. Of 51 women who screened positive for CT/NG at first ANC and returned for test-of-cure, 100% reported notifying their partner and 48 (94.1%) reported their partner received treatment. At third trimester 100% (n = 5) reported partners were treated. Prior to testing, EPT intent was lower than EPT uptake at all timepoints (first ANC: 17.9% vs. 80.4%; third-trimester 57.1% vs. 71.4%; PNC: 0% vs. 80.0%). Partner treatment success was 100% among EPT users compared to 70% among non-users (p = 0.006). Partner notification and treatment success was high in this population. Despite low pre-test intent to use EPT, uptake was high and associated with greater partner treatment success. Our findings suggest that EPT may be a successful partner treatment strategy to pursue in LMICs.

Sections du résumé

BACKGROUND BACKGROUND
Partner notification and treatment for sexually transmitted infections is critical to prevent reinfection and reduce transmission. However, partner treatment rates are low globally. Expedited Partner Therapy (EPT), in which the patient delivers treatment directly to their partner, may result in more partners treated. We assessed partner notification and treatment outcomes among pregnant women in Gaborone, Botswana, including EPT intent, uptake, and effectiveness.
METHODS METHODS
The Maduo study was a cluster-controlled trial evaluating the effect of antenatal C. trachomatis (CT) and N. gonorrhoeae (NG) infection screening in pregnant women. The intervention arm received screening at first antenatal care (ANC), third-trimester, and postnatal care (PNC) visits. The standard-of-care arm received screening postnatally. Participants screening positive were given options for partner treatment: contact slips, in-clinic treatment, or EPT. Self-reported partner notification and treatment outcomes were assessed at test-of-cure visit.
RESULTS RESULTS
Of 51 women who screened positive for CT/NG at first ANC and returned for test-of-cure, 100% reported notifying their partner and 48 (94.1%) reported their partner received treatment. At third trimester 100% (n = 5) reported partners were treated. Prior to testing, EPT intent was lower than EPT uptake at all timepoints (first ANC: 17.9% vs. 80.4%; third-trimester 57.1% vs. 71.4%; PNC: 0% vs. 80.0%). Partner treatment success was 100% among EPT users compared to 70% among non-users (p = 0.006).
CONCLUSIONS CONCLUSIONS
Partner notification and treatment success was high in this population. Despite low pre-test intent to use EPT, uptake was high and associated with greater partner treatment success. Our findings suggest that EPT may be a successful partner treatment strategy to pursue in LMICs.

Identifiants

pubmed: 38301627
doi: 10.1097/OLQ.0000000000001928
pii: 00007435-990000000-00304
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Sexually Transmitted Diseases Association. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of Interest Statement: The authors have no competing interests to disclose.

Auteurs

Rebecca Ryan (R)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Plot No. 1836, Northring Road, Gaborone, Botswana.

Chibuzor M Babalola (CM)

Keck School of Medicine, University of Southern California, 1845 N. Soto Street, Los Angeles, California, 90032, USA.

Kehumile Ramontshonyana (K)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Plot No. 1836, Northring Road, Gaborone, Botswana.

Lefhela Tamuthiba (L)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Plot No. 1836, Northring Road, Gaborone, Botswana.

Neo Ndlovu (N)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Plot No. 1836, Northring Road, Gaborone, Botswana.

Bame Bame (B)

Botswana Harvard AIDS Institute Partnership, Princess Marina Hospital, Plot No. 1836, Northring Road, Gaborone, Botswana.

Jeffrey D Klausner (JD)

Keck School of Medicine, University of Southern California, 1845 N. Soto Street, Los Angeles, California, 90032, USA.

Adriane Wynn (A)

University of California, San Diego, Division of Infectious Diseases and Global Public Health, 9500 Gilman Drive, La Jolla, CA 92093 USA.

Classifications MeSH